Drug Trial Radar · NCT07550387
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
363
Actual
Start
May 23, 2024
Primary completion
Jan 2, 2026
Study completion Jan 19, 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, randomized, double-blind, parallel-group, active-controlled and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of HS-10380 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate the response rate, improvement in disease severity and symptoms, safety and tolerability, and pharmacokinetics.
Conditions
- SCHIZOPHRENIA 1 (Disorder)
Interventions
HS-10380 Low DoseDrug
W1:dose titration; W 2-3 dose adjust to optimal level;Week 4-6:stable dose
HS-10380 Medium doseDrug
W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose
HS-10380 High DoseDrug
W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose
AripiprazoleDrug
W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose
PlaceboDrug
W1: dose titration; W 2-3: dose adjust to optimal level; Week 4-6: stable dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (Day 42)Time frame: Baseline and Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.